Lexicon Pharmaceuticals (NASDAQ: LXRX) director receives new option and RSU awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS director Diane E. Sullivan received new equity awards as part of her compensation. On May 1, 2026, she was granted stock options covering 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. The option vests in three equal annual installments on each of the first three anniversaries of the grant date.

She was also granted 35,714 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest in full on the first anniversary of the grant date. These are non-cash, compensation-related grants, with no open-market purchases or sales reported in this filing.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sullivan Diane E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	35,714	$0.00	--
Grant/Award	Stock Option (Right to Buy)	43,478	$0.00	--

Holdings After Transaction: Restricted Stock Units — 35,714 shares (Direct, null); Stock Option (Right to Buy) — 43,478 shares (Direct, null)

Footnotes (1)

Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Key Figures

Stock options granted: 43,478 shares Option exercise price: $1.61 per share Option expiration: May 1, 2036 +5 more

8 metrics

Stock options granted 43,478 shares Grant to Diane E. Sullivan on May 1, 2026

Option exercise price $1.61 per share Stock option grant exercise price

Option expiration May 1, 2036 Stock option term end date

RSUs granted 35,714 units Restricted stock units granted May 1, 2026

RSU vesting 100% after 1 year RSUs vest on first anniversary of grant date

Option vesting schedule 1/3 per year over 3 years Beginning first anniversary of grant date

Underlying common shares (options) 43,478 shares Common stock underlying stock option grant

Underlying common shares (RSUs) 35,714 shares Common stock underlying RSU grant

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), contingent right to receive one share, vests, +1 more

5 terms

Restricted Stock Units financial

"security_title: "Restricted Stock Units" and footnote defining each unit"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" describing derivative award"

vests financial

"Restricted stock unit vests with respect to 100% of the shares"

exercise price financial

"conversion_or_exercise_price: "1.6100" for the stock option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Diane E.

(Last)

(First)

(Middle)

2445 TECHNOLOGY FOREST BLVD.

11TH FLOOR

(Street)

THE WOODLANDS

TEXAS

77381

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	05/01/2026		A		35,714		⁽¹⁾	⁽²⁾	Common Stock	35,714	$0	35,714	D
Stock Option (Right to Buy)	$1.61	05/01/2026		A		43,478		⁽³⁾	05/01/2036	Common Stock	43,478	$0	43,478	D

Explanation of Responses:

1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

2. Each restricted stock unit represents a contingent right to receive one share of common stock.

3. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

	/s/ Diane E. Sullivan	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Diane E. Sullivan report in this Form 4 for LXRX?

Diane E. Sullivan reported equity compensation grants from Lexicon Pharmaceuticals. She received stock options and restricted stock units, increasing her potential common stock holdings without any open-market buying or selling activity disclosed in this filing.

How many stock options did Diane E. Sullivan receive from Lexicon Pharmaceuticals (LXRX)?

She received stock options covering 43,478 shares of Lexicon common stock. These options have an exercise price of $1.61 per share and a ten-year term, expiring on May 1, 2036, subject to scheduled vesting.

What are the vesting terms of Diane Sullivan’s RSU grant at LXRX?

The restricted stock unit grant of 35,714 units vests 100% on the first anniversary of the May 1, 2026 grant date. Each vested RSU entitles her to receive one share of Lexicon Pharmaceuticals common stock.

How do Diane Sullivan’s stock options at Lexicon Pharmaceuticals vest?

Her stock options vest in three equal installments. One third of the 43,478 option shares vest on each of the first three anniversaries of the May 1, 2026 grant date, provided the award conditions continue to be met.

Does this Lexicon Pharmaceuticals Form 4 show any insider stock sales or purchases?

No open-market stock sales or purchases are shown. The filing reports compensation-related grants of stock options and restricted stock units to director Diane E. Sullivan, both classified as acquisitions rather than market transactions.